News|Articles|January 28, 2026
Enhanced Paveway™ PLUS Selects Expression Organisms Based on Titer Plus Quality
Author(s)Fujifilm
Discover the future of microbial expression with a platform that optimizes strain selection, expression systems, and purification methods, providing actionable insights in just eleven weeks.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
HanchorBio–WuXi Biologics Partnership Targets Fusion Protein Development Challenges
2
GSK’s Arexvy Gains EU Approval for Adults Aged 18 Years and Older
3
FDA Fast Tracks Innovent’s Trispecific Antibody for Multiple Myeloma
4
Subvisible Particulate Matter Testing
5